Lantheus Holdings stock faces an October 14 merger vote

Published on 10/04/2026 at 13:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lantheus Holdings stock heads toward an October 14, 2026, merger vote after three complaints and 16 demand letters were disclosed. Q2 revenue reached USD 388.18 million.

LANT, US5165441032, Illustration mit AI erstellt.

Lantheus Holdings stock was last at USD 99.96 on Nasdaq on October 2, 2026, at 4:00 p.m. ET, up 0.31 percent from the prior close. The immediate catalyst is the proposed Curium transaction and a new filing that details litigation and supplemental merger disclosures ahead of the October 14, 2026, shareholder vote.

Merger scrutiny reaches the vote

According to StockTitan on October 2, 2026, Lantheus disclosed three merger-related complaints and 16 demand letters received by September 30, 2026. The complaints challenge disclosures concerning financial projections, Morgan Stanley's fairness analysis and possible insider conflicts, while Lantheus provided supplemental information without admitting liability.

The same filing states that Morgan Stanley's discounted cash flow analysis implied USD 88.10 to USD 118.60 per share. Its public-company analysis produced USD 63.85 to USD 84.20, placing the current USD 99.96 reference price inside the DCF range but above the public-company range.

Revenue provides a second anchor

Lantheus reported Q2 2026 revenue of USD 388.18 million, up 2.7 percent from the year-earlier quarter, according to MarketBeat in its October 1, 2026, report. The company operates in diagnostic and therapeutic products, with radiopharmaceuticals and medical imaging at the center of its portfolio.

The company also received CMS transitional pass-through status for PYLARIFY TruVu effective October 1, 2026, alongside a permanent HCPCS code, as Lantheus Holdings announced on September 30, 2026. That designation supports separate reimbursement in hospital outpatient settings and gives the product a commercial access milestone.

Consensus sits above the quote

MarketBeat reported on October 1, 2026, that 14 firms carry a Hold consensus, including 10 Hold ratings and four Buy ratings. The average 12-month price target is USD 108.11, which lies 8.2 percent above the USD 99.96 reference price.

Stock remains below its yearly high

Lantheus Holdings stock had a market capitalization of USD 6.5 billion and traded within a 52-week range of USD 49.67 to USD 111.86 on October 2, 2026. Volume was 705,952 shares, making the October 14 vote and the merger disclosures the next concrete checkpoints for the Nasdaq-listed company.